ACCREDITATION
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE
Attending physicians, researchers, house staff, fellows, residents, medical students, nurses.

NEEDS ASSESSMENT
The talk will include a summary of the current state of understanding of anti-cancer immune therapies, methods of identifying potential immune-oncology therapeutic targets, and approaches to test these new therapies.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:
• Describe the critical features of anti-cancer immune responses
• Recognize the histopathological characteristics of immune-mediated tumor eradication
• Understand approaches to identifying and developing novel immune-oncology therapies

DESIGNATION STATEMENT
The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES
Speaker Name: Marcus Bosenberg, MD, PhD - Eli Lilly and Company, Consultant
Course Directors: Manju Prasad, MD - None
Kurt Schaper, MD, PhD - None
Pallavi Gopal, MD, PhD - None
It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.

There is no corporate or grant support for this activity. This course will fulfill the licensure requirement set forth by the State of Connecticut.

Thursday, October 10, 2019
12:30 p.m.
Fitkin Amphitheater – LMP 1094

Host: Manju Prasad, MD

"Developing Effective Immuno-oncology Therapies"